HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lynsey Whittaker Selected Research

vandetanib (ZD6474)

12/2004ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lynsey Whittaker Research Topics

Disease

2Neoplasms (Cancer)
05/2005 - 12/2004
1Prolactinoma (Prolactinomas)
05/2005
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
12/2004

Drug/Important Bio-Agent (IBA)

2bisbenzimide ethoxide trihydrochloride (Hoechst 33342)IBA
05/2005 - 12/2004
1Biomarkers (Surrogate Marker)IBA
05/2005
1N-acetylcochinol-O-phosphateIBA
05/2005
1ErbB Receptors (EGF Receptor)IBA
12/2004
1vandetanib (ZD6474)IBA
12/2004
1Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
12/2004
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
12/2004

Therapy/Procedure

1Aftercare (After-Treatment)
05/2005
1Intravenous Administration
12/2004
1Radiotherapy
12/2004